Permissible Provider Collaborations During Covid & Beyond - McDermott

On The Horizon: Permissible Provider Collaborations During Covid-19 and Beyond

Overview



As the healthcare industry continues to cope with the Coronavirus (COVID-19) and form strategic and short- and long-term plans, providers are faced with numerous decisions that have critical antitrust implications. Whether seeking to collaborate with competitors for pandemic response or exploring potential transactional opportunities, there are both traditional antitrust guidelines and COVID-specific developments applicable to these business decisions.

Please join our team of health antitrust lawyers as they explore navigating compliance concerns and strategic antitrust considerations that providers should address as they contemplate and pursue cooperative relationships.

This webinar will offer insights on guardrails of collaboration in light of the pandemic, including:

  • Planning for COVID-19 related allocation issues, such as patient transfers, supplies and staffing
  • Avoiding antitrust violations in labor markets, particularly related to employee recruiting and wage arrangements
  • Navigating distressed deal opportunities and the failing firm defense
  • Considerations for strategic deal opportunities such as minority investment joint ventures

We want to ensure we address the issues of most importance to our participants, and we encourage you to submit your questions for the panel in advance during registration.

Dig Deeper

Nashville, TN / McDermott Event / May 6-9, 2025

McDermott HealthEx

Paris, France / McDermott Event / April 2, 2025

European Health & Life Sciences Symposium 2025

Miami, FL / McDermott Event / March 5-6, 2025

HPE Miami 2025

San Francisco, CA / McDermott Event / January 14, 2025

McDermott Forum During the 2025 J.P. Morgan Healthcare Conference

Get In Touch